MYOK News and Press, MyoKardia Inc. From 08/03/20

The first patient has been dose d in a Phase 3 clinical, VALOR-HCM , evaluating MyoKardia's ( MYOK -0.5% ) mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) who have been referred for septal reduction therapy (SRT) and are refractory to current therapeutic options...

BRISBANE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) announced that the first patient has been dosed in the Phase 3 VALOR-HCM clinical trial.  VALOR-HCM will enroll individuals with obstructive hypertrophic cardiomyopathy (HCM) who have been referred for s...

BRISBANE, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter financial and operating results on Tuesday, August 4, 2020. Management will host a conference call and live audio webcast to discuss these results and provi...

BRISBANE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to mavacamten, a novel, oral, allosteric modulator of cardiac myosin, for the treatment of symptom...

MyoKardia (NASDAQ: MYOK ) has collaborated with Fulcrum Therapeutics (NASDAQ: FULC ) , to discover, develop and commercialize novel targeted therapies for genetic cardiomyopathies. More news on: MyoKardia, Inc., Fulcrum Therapeutics, Inc., Healthcare stocks news, Read mo...

BRISBANE, Calif. and CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases and Fulcrum Therapeutics, Inc. (Nasdaq: FULC...

MyoKardia Reports Upbeat Phase 2a Clinical Data MyoKardia Inc. ( MYOK ) announced that its Phase 2a clinical trial of danicamtiv has yielded positive results. The company also discussed nonclinical data showing the novel mechanism of action of the drug candidate. Danicamtiv is MyoKar...

MyoKardia ( MYOK -0.8% ) announces positive results from a Phase 2a clinical trial evaluating danicamtiv in stable heart failure patients with reduced ejection fraction. The data were presented virtually at the European Society of Cardiology's Heart Failure Association Discoveries even...

Danicamtiv was Well Tolerated;  Demonstrated Improvements in Cardiac Contractility and Preserved Diastolic Function in Patients with Stable Heart Failure with Reduced Ejection Fraction New Observations Show Improvements in Left Atrial Volume and Function, Key Prognostic Indicator...

-- MyoKardia to Host Conference Call at 8:30 a.m. ET on Monday, June 22, 2020 -- BRISBANE, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that data from the company’s Phase 2a multiple-ascending dose study of danicamtiv (formerly MYK-491...